Exact Sciences | EXAS

Stock Price
53.81
Daily Change
2.40 4.67%
Monthly
14.71%
Yearly
-8.97%
Q3 Forecast
53.36

Peers Price Chg Day Year Date
Agilent 128.75 0.27 0.21% -6.04% Sep/05
Becton, Dickinson and Co. 192.39 1.13 0.59% -17.28% Sep/05
Bio-Rad Laboratories 295.43 6.00 2.07% -10.48% Sep/05
Bruker 30.83 1.04 3.49% -51.84% Sep/05
Charles River Laboratories 163.99 1.68 1.04% -12.63% Sep/05
Danaher 200.21 1.18 0.59% -24.77% Sep/05
Exact Sciences 53.81 2.40 4.67% -8.97% Sep/05
Hologic 66.76 0.37 0.56% -18.16% Sep/05
Illumina 98.93 1.25 1.28% -20.47% Sep/05
Mettler Toledo International 1,305.71 17.92 1.39% -5.26% Sep/05
Myriad Genetics 6.61 -0.18 -2.65% -75.49% Sep/05
Revvity 86.64 0.94 1.10% -24.90% Sep/05
Quidel 28.68 0.89 3.20% -33.99% Sep/05
Repligen 124.56 3.98 3.30% -15.31% Sep/05
STAAR Surgical 27.94 0.16 0.58% -10.22% Sep/05
Bio Techne 54.41 1.49 2.82% -24.00% Sep/05
Thermo Fisher Scientific 492.60 3.11 0.64% -19.59% Sep/05
Veracyte 32.43 0.91 2.89% 13.51% Sep/05
Waters 306.32 6.63 2.21% -6.72% Sep/05

Indexes Price Day Year Date
USND 21700 -7.31 -0.03% 30.01% Sep/05
US2000 2391 11.44 0.48% 14.33% Sep/05

Exact Sciences traded at $53.81 this Friday September 5th, increasing $2.40 or 4.67 percent since the previous trading session. Looking back, over the last four weeks, Exact Sciences gained 14.71 percent. Over the last 12 months, its price fell by 8.97 percent. Looking ahead, we forecast Exact Sciences to be priced at 53.36 by the end of this quarter and at 52.05 in one year, according to Trading Economics global macro models projections and analysts expectations.

Exact Sciences Corporation is a cancer screening and diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer and Oncotype DX. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The Cologuard test is intended for the qualitative detection of colorectal neoplasia associated DNA markers and for the presence of occult hemoglobin in human stool. It focuses on the development of additional tests for other types of cancer. It is developing a blood-based biomarker test to aid in the early detection of lung cancer in individuals with lung nodules discovered through a computerized tomography (CT) scan.